Boehringer’s Jascayd gains China’s NMPA approval for PPF
China’s National Medical Products Administration (NMPA) has granted approval for Boehringer Ingelheim’s Jascayd (nerandomilast) to treat progressive pulmonary fibrosis (PPF).…
11 Dec 2025
Formation Bio gains global rights to Lynk Pharma’s TYK2 inhibitor
Formation Bio has acquired the global rights, excluding in Greater China, to LNK01006, a highly selective tyrosine kinase 2 (TYK2) inhibitor from Lynk Pharmaceuticals. This next-generation central nervous system (CNS)-penetrant…
10 Dec 2025
Cell and gene therapy investment strategy pivots as funding dries up
Companies looking to push into the gene therapy (CGT) sector are navigating a more selective funding landscape amid a wider downturn in venture capital investment. According to a report by…
10 Dec 2025
Eli Lilly picks Alabama as home to $6bn orforglipron manufacturing facility
American pharmaceutical giant Eli Lilly has tapped Huntsville, Alabama, as the location for its third orforglipron manufacturing facility. Set to enter construction in 2026, the $6bn site will create 3,000…
10 Dec 2025
Formycon and Zydus sign exclusive agreement for FYB206 supply
Formycon and Zydus Lifesciences have entered an exclusive licensing and supply agreement for FYB206, a biosimilar of MSD’s Keytruda (Pembrolizumab), in Canada and the US. Formycon will complete the development…
10 Dec 2025
Health Canada approves Biogen’s Zurzuvae for PPD treatment
Biogen has received a notice of compliance (NOC) from Health Canada for Zurzuvae (zuranolone), a neuroactive steroid (NAS), as a treatment for moderate or severe postpartum depression (PPD) in women. The…
09 Dec 2025
BIOSECURE Act set for Congress vote after inclusion in annual defence bill
After years in legislative limbo, the BIOSECURE Act – albeit with a softer framework – is poised to enter the home stretch on Capitol Hill before being enacted into US…